esrakarabag.dr@hotmail.com
2Ruveyda Gulmez, akerruveyda@gmail.com
2Nur Canpolat, ncanpolat2000@hotmail.com
1Ayca Kiykim, ayca.kiykim@iuc.edu.tr
1Haluk Cezmi Cokugras, cokugras@gmail.com
1Istanbul University-Cerrahpasa, Department of Pediatric Immunology and Allergy, Istanbul
2Istanbul University-Cerrahpasa, Department of Pediatric Nephrology, Istanbul
  1. Rovin BH, Adler SG, Barratt J et al (2021) Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 100:753–779.
  2. Ataca P, Atilla E, Kendir R, Bavbek S, Ozcan M. Successful desensitization of a patient with rituximab hypersensitivity. Case Reports Immunol. 2015;2015:524507.
  3. D. I. Hong, L. Bankova, K. N. Cahill, T. Kyin, and M. C. Castells. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Review of Clinical Immunology, vol. 8, no. 1, pp. 43–54, 2012.
  4. Pichler WJ, Hausmann O. Classification of drug hypersensitivity into allergic, p-i, and pseudo-allergic forms. Int Arch Allergy Immunol 2016; 171:166 – 179.
  5. Bumbacea RS, Ali S, Corcea SL, Spiru L, Nitipir C, Strambu V, Bumbacea D. Omalizumab for successful chemotherapy desensitisation: What we know so far. Clin Transl Allergy. 2021 Dec 13;11(10):e12086.
  6. Taha R, El-Haddad H, Almuallim A, Alshaiki F, Obaid E, Almoallim H. Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schönlein purpura, ankylosing spondylitis, and Raynaud’s phenomenon. Open Access Rheumatol 2017;9:201-14.
  7. Görgülü B, Seval GC, Kendirlinan R, Toprak SK, Özcan M, Bavbek S. Rapid Drug Desensitization With Rituximab in 24 Cases: A Single-Center Experience. J Investig Allergol Clin Immunol. 2019;29(6):468-470.
  8. Isabwe GAC, Neuer MG, de las Vecillas Sanchez L, Lynch DM, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol. 2018;142(1):159-71
  9. Fernandez J, Ruano-Zaragoza M, Blanca-Lopez N. Omalizumab and other biologics in drug desensitization. Curr Opin Allergy Clin Immunol. 2020 Aug;20(4):333-337.
  10. Arroabarren E, Aznal E, Anda M, Sanchez-Valverde F. Anaphylaxis after Elosulfase A infusion: Omalizumab as coadjuvant for enzyme replacement therapy desensitization. Pediatr Allergy Immunol. 2019 Jun;30(4):491-494.